Exploring the effects of LEAP2 hormone on glucose metabolism in obesity
Effects of Antagonizing the Ghrelin Receptor on Total-body Glucose Metabolism in Obesity
This study is testing if the hormone LEAP2 can improve how the body processes sugar in people with obesity.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 9 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | Male |
| Sponsor | University Hospital, Gentofte, Copenhagen Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Hellerup, Capital Region) |
| Trial ID | NCT06254365 on ClinicalTrials.gov |
What this trial studies
This study investigates the role of the hormone LEAP2 in glucose metabolism, particularly in individuals with obesity. Participants will undergo two experimental days, receiving either LEAP2 or a placebo infusion in a randomized order. The effects on glucose metabolism will be assessed using total-body PET/CT scans, aiming to enhance understanding of the interaction between LEAP2 and the hunger hormone ghrelin. The findings may provide valuable references for future research in this area.
Who should consider this trial
Good fit: Ideal candidates are Caucasian adults aged 18 to 60 with a body mass index between 30 and 50 kg/m2.
Not a fit: Patients with type 2 diabetes requiring medical treatment or significant liver or kidney disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new insights and treatments for obesity by targeting glucose metabolism.
How similar studies have performed: While the role of LEAP2 is being explored, this specific approach using total-body PET/CT scans is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Caucasian * Age between 18 and 60 years at the time of inclusion * Body mass index 30-50 kg/m2 * Informed consent Exclusion Criteria: * Anaemia (haemoglobin below normal range) * Alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) ≥2 times normal values) or present hepatobiliary and/or gastrointestinal disorder(s) * Nephropathy (serum creatinine above normal range and/or albuminuria) * Glycated haemoglobin (HbA1c) ≥48 mmol/mol and/or type 2 diabetes requiring medical treatment * Regular tobacco smoking or use of other nicotine-containing products * Claustrophobia * Any ongoing medication that the investigator evaluates would interfere with trial participation. * Any physical or psychological condition that the investigator evaluates would interfere with trial participation including any acute or chronic illnesses
Where this trial is running
Hellerup, Capital Region
- Center for Clinical Metabolic Research, Gentofte Hospital — Hellerup, Capital Region, Denmark (Recruiting)
Study contacts
- Principal investigator: Filip K Knop, MD, PhD, Professor — Center for Clinical Metabolic Research, Gentofte Hospital
- Study coordinator: Anders Englund, MD, PhD-student
- Email: anders.englund@regionh.dk
- Phone: +4530541484
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.